博爱女性医院好不好(哈密慢性前列腺炎医院) (今日更新中)

SAN FRANCISCO, May 10 (Xinhua) -- Google on Tuesday launched its long-awaited cloud-based music service Music Beta without any label licenses it originally wanted.The search giant introduced the digital music locker service at its annual I/O developer conference in San Francisco. So far, only U.S. users can access the service by requesting an invitation from Google while priorities will be given to those with the Verizon version of the Motorola Xoom tablet and attendees of the I/O conference.Since Google failed to come to a license agreement with major music labels, Music Beta is essentially a massive cloud hard drive. Users cannot share their Music Beta by Google tunes or purchase new songs. It allows users to upload 20,000 songs into the cloud, compared with Amazon Cloud Drive's 2,000 songs and 5 GB limit for free accounts.Any web-connected devices with a browser or supporting Flash can stream music from the digital locker, but the service is only for Android-powered devices.Music Beta also gets Instant Mix, a similar intelligent feature to Apple's Genius playlist creator, which creates new playlists based on a single song by analyzing its characteristics.Before unveiling the service, Google told U.S. media Monday night that the current Music Beta is not the service Google had wanted to offer and it will continue to seek licenses with major music labels.

LOS ANGELES, April 14 (Xinhua) -- Vegetarians experience a much lower risk of metabolic syndrome than non-vegetarians, U.S. researchers have found.Researchers at Loma Linda University in California based their findings on analysis of more than 700 adults randomly sampled from a long-term study of the lifestyle and health of almost 100,000 Seventh-day Adventist Christians across the United States and Canada.While 25 percent of vegetarians had metabolic syndrome, the number significantly rises to 37 percent for semi-vegetarians and 39 percent for non-vegetarians, according to the study published in the April issue of the journal Diabetes Care.The findings showed that the risk of developing metabolic syndrome is 36 percent lower among vegetarians than non- vegetarians.This means that vegetarians are less likely to develop heart disease, diabetes and stroke -- three major conditions that are closely linked with metabolic syndrome, the researchers say.The study also found that vegetarians, though slightly older than non-vegetarians, had lower triglycerides, glucose levels, blood pressure, waist circumference, and body mass index (BMI). Semi-vegetarians, meanwhile, also had a significantly lower BMI and waist circumference compared to those who ate meat more regularly.The findings will not be affected by other factors such as age, gender, race, physical activity, calories consumed, smoking, and alcohol intake, the researchers say."In view of the high rate of metabolic syndrome in the United States and its deleterious health effects, we wanted to examine lifestyle patterns that could be effective in the prevention and possible treatment of this disorder," says lead researcher Nico S. Rizzo, PhD."I was not sure if there would be a significant difference between vegetarians and non-vegetarians, and I was surprised by just how much the numbers contrast," he says. "It indicates that lifestyle factors such as diet can be important in the prevention of metabolic syndrome."

You can think of NASA's Discovery program as a sort of outer-space American Idol: every few years the agency invites scientists to propose unmanned planetary missions. The projects have to address some sort of fundamental science question, and (this is the tough part) they have to be relatively cheap to pull off — say, half a billion dollars or so. Then the proposals go through a grueling competition before judges who aren't as nasty as Simon Cowell but who are every bit as tough. The one left standing at the end gets the equivalent of a recording contract: NASA supplies the funding and the launch vehicle, and away the winner goes — to orbit Mercury, as the Messenger spacecraft is doing right now; or to rendezvous with a couple of asteroids, as the Dawn mission will start doing this July; or to smash into a comet on purpose, a feat achieved by Deep Impact in 2005, a mission not to be confused with the movie of the same name. Now it's time for the next contenders. NASA has just announced that the first round of the latest Discovery competition is over, with three entries out of 28 moving on to the finals. They are, in increasing distance from Earth: the Geophysical Monitoring Station (GEMS) lander, which would use seismometers to study the interior of Mars; the Comet Hopper, which would do just that, leaping from place to place across the surface of Comet 46P/Wirtanen to see how different parts of the tumbling body react to heating by the sun; and the Titan Mare Explorer (TiME), which would plop into a sea of liquid hydrocarbons on Saturn's moon Titan — the first oceangoing vessel ever to set sail on another world. If you had to come up with a theme that ties all three missions together, it would be "origins." The Titan explorer, for example, will be studying a place that — in a crude way, at least — resembles the early planet Earth at a time when life arose here. Titan, with a thick atmosphere and a bizarro-world form of weather featuring toxic winds and hydrocarbon rain, is home to a mix of complex chemistry, complete with organic molecules. The oceans provide a medium in which the molecules can move around and interact with each other. It's even conceivable, though clearly a long shot, that some form of microscopic life already exists on this frigid moon. The Mars lander, by contrast, would visit a place where the seas — plain water in this case — vanished long ago. But the mission of GEMS goes far deeper than that. By analyzing Marsquakes on the Red Planet, GEMS will try to get a handle on what the interior of Mars is like. Scientists don't currently know whether the planet's core is liquid, like Earth's, or solid, or some mushy consistency in between. It all depends on how efficiently Mars has cooled since it formed 4.5 billion years ago, and that depends in turn on the planet's internal structure. "That's the mission," says Bruce Banerdt, of NASA's Jet Propulsion Laboratory, the lead scientist for GEMS. "We want to understand how Mars was built." Along with sensitive seismographic equipment, GEMS will drill down about 20 ft. (6 m) with a thermometer-equipped probe, trying to figure out how quickly the temperature rises with depth. "That will let us extrapolate all the way down to the center," Banerdt says, "which will tell us how fast Mars is cooling."

WASHINGTON, May 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Sutent to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body.Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.This is the second new approval by the FDA to treat patients with this disease. On May 5, the agency approved Afinitor."FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to bring innovative new therapies to the market and encourages companies to continue exploring additional uses for approved products."The safety and effectiveness of Sutent was established in a single study of 171 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease who received Sutent or a placebo (sugar pill). The study was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).Results from the study demonstrate that Sutent provided benefit to patients by prolonging the median length of time they lived without the cancer spreading or worsening to 10.2 months compared to 5.4 months for patients who received placebo.In patients treated with Sutent for neuroendocrine pancreatic tumors, the most commonly reported side effects included diarrhea, nausea, vomiting, fatigue, anorexia, high blood pressure, energy loss, stomach pain, changes in hair color, inflammation of the mouth, and a decrease in infection-fighting white blood cells.Sutent is marketed by New York City-based Pfizer.

BEIJING, April 19 (Xinhuanet) -- The case in the Hollywood blockbuster "The Social Network" continues in real life.Twins Cameron and Tyler Winklevoss on Monday filed another appeal against their Harvard classmate and Facebook founder Mark Zuckerberg.The Winklevosses claim that the case needs to be reviewed by a special 11-judge panel in the latest appeal, after a three-judge panel of the 9th U.S. Circuit Court of Appeals ruled against the brothers last week.The twins initially claimed that Zuckerberg had stolen their idea for the website but agreed to drop their lawsuit in 2008 in exchange for 20 million dollars in cash and stock in the company.But later they discovered the stock was worth less than claimed at the time and sought to have the deal voided, the brothers said.

来源：资阳报